[1]李惠平.153Sm-EDTMP治疗骨转移癌疼痛的现状[J].国际放射医学核医学杂志,2000,24(3):113-116.
　LI Hui-ping.Treatment status of painful bone metastases with 153Sm-EDTMP[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(3):113-116.
点击复制

153Sm-EDTMP治疗骨转移癌疼痛的现状(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
24
期数:
2000年第3期
页码:
113-116
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Treatment status of painful bone metastases with 153Sm-EDTMP
作者:
李惠平
100083 北京, 北京大学第三医院肿瘤化疗放射病科
Author(s):
LI Hui-ping
Department of Radiation Medicine, Third Hospital Beijing University, Beijing 100083, China
关键词:
转移癌; 疼痛; 153Sm-乙二胺四甲撑膦酸
Keywords:
bone metastases; pain; 153Sm-ethylenediaminetet ramethylene phosphonat
分类号:
R817. 5
摘要:
以往骨转移癌病人疼痛治疗的常用方法是放疗和阶梯性使用止痛药物。随着核医学的发展,亲骨性放射性核素越来越多地用于癌症的治疗,尤其是骨转移癌的止痛治疗。其中,153Sm-EDTMP(153Sm-乙二胺四甲撑膦酸)在缓解疼痛,改善生活质量,减少新的骨转移病灶发生,及降低治疗费用等方面都有很大优势。
Abstract:
The typical management of painful bone metastases is radiation therapy and the graduated use of opiate analgesics. As the development of nuclear medicine,bone-seeking radiopharmaceuticals have been utilized in cancer treatment,especially in management painful bone metastases. 153Sm-EDTMP (samarium 153 ethylenediaminetetramethylene phosphonate) offers a good choice of treating method in palliating pain, improving quality of life, decreasing the rate at which new painful sites develop, and decreasing management costs.

参考文献/References:

[1] Lewington VJ. Cancer therapyusing bone-seeking isotopes[J]. Phys Med Biol, 1996, 41(10):2027~2042.
[2] Pusuwan P, Chaiwatanarat T, Chaudakshetrin P, et al.Pharmacokinetics of samarium-153-EDTMP in disseminated skeletal metastases[J]. J Med Assoc Thai, 1996, 79(9):579~584.
[3] Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam:a double-blind placebo-controlled clinical trial[J]. J Clin Oncol, 1998, 16(4):1574~1581.
[4] Resche JF, Catal A, Pecking P, et al. A Dose-controlled study of 153 Sm-ethylenediaminetetramethylene-phosphonate (EDTMP) in the treatment of patients with painful bone metastases[J]. Eur J Cancer, 1997,33(10):1583~1591.
[5] Bruland OS, Skretting A, Solheim OP, et al. Targeted radlotherapy of osteosarcoma using 153 Sm-EDTMP:A new promising approach[J]. Acta Oncol, 1996, 35(3):381~384.
[6] Alberts AS, Smit BJ, Louw WK, et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone[J]. Radiother Oncol, 1997, 43(2):175~179.
[7] Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylenediaminetetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China[J]. Eur J Nucl Med, 1999, 26(1):2~7.
[8] McEwan AJ. Unsealed source therapy of painful bone metastases:an update[J]. Semin Nucl Med, 1997, 27(2):165~182.
[9] Cameron PJ, Klemp PF, Martindale AA, et al. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy[J]. Nucl Med Commun, 1999, 20(7):609~615.

相似文献/References:

[1]顾涛颖,石洪成.放射性药物治疗肿瘤骨转移性骨痛的作用[J].国际放射医学核医学杂志,2010,34(2):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
　GU Tao-ying,SHI Hong-cheng.The use of radiopharmaceuticals for metastatic bone pain in cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]

备注/Memo

备注/Memo:
收稿日期:1999-03-11。
作者简介:李惠平(1962-),女,山西武乡人,北京大学第三医院肿瘤化疗放射病科副主任医师,硕士,主要从事造血损伤与修复的研究。
更新日期/Last Update: 1900-01-01